The next generation biopharmaceuticals

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibodys latest Press releases

To the archive

2021-03-09

Affibody and Inmagene announce IND Clearance for izokibep (ABY-035) for the treatment of Non-infectious Non-anterior Uveitis

San Diego, U.S., Shanghai, China, and Solna, Sweden, March 9, 2021. Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced that the U.S. FDA...[read more]

2021-02-19

Year End Report 2020...[read more]

2021-02-10

Affibody and Inmagene announce IND Clearance for Izokibep (ABY-035) for the...[read more]